Healthcare provider profile · identity verified

Martin J Herrmann, MD

Family Practice · NEW PRAGUE, MN · NPI 1821036054

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	372	99
Losartan Potassium	Losartan Potassium	176	50
Lisinopril	Lisinopril	174	57
Amlodipine Besylate	Amlodipine Besylate	173	55
Levothyroxine Sodium	Levothyroxine Sodium	156	40
Omeprazole	Omeprazole	127	35
Metoprolol Succinate	Metoprolol Succinate	125	36
Rosuvastatin Calcium	Rosuvastatin Calcium	114	35
Warfarin Sodium	Warfarin Sodium	101	14
Furosemide	Furosemide	95	25
Metformin Hcl	Metformin Hcl	93	26
Hydrochlorothiazide	Hydrochlorothiazide	87	27
Eliquis	Apixaban	84	17
Allopurinol	Allopurinol	82	17
Pantoprazole Sodium	Pantoprazole Sodium	78	22
Gabapentin	Gabapentin	74	21
Tamsulosin Hcl	Tamsulosin Hcl	72	25
Metoprolol Tartrate	Metoprolol Tartrate	70	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	61	13
Jantoven	Warfarin Sodium	56	15
Simvastatin	Simvastatin	53	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	45	14
Sertraline Hcl	Sertraline Hcl	44	11
Prednisone	Prednisone	41	32
Trazodone Hcl	Trazodone Hcl	39	suppressed
Finasteride	Finasteride	38	suppressed
Clopidogrel	Clopidogrel Bisulfate	37	14
Metformin Hcl Er	Metformin Hcl	37	14
Citalopram Hbr	Citalopram Hydrobromide	36	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	35	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	34	suppressed
Pravastatin Sodium	Pravastatin Sodium	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Duloxetine Hcl	Duloxetine Hcl	31	11
Montelukast Sodium	Montelukast Sodium	31	suppressed
Spironolactone	Spironolactone	28	11
Oxybutynin Chloride	Oxybutynin Chloride	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Glipizide Er	Glipizide	26	suppressed
Chlorthalidone	Chlorthalidone	24	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	24	suppressed
Fluticasone Propionate	Fluticasone Propionate	24	13
Carvedilol	Carvedilol	23	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	23
Glipizide	Glipizide	23	suppressed
Xarelto	Rivaroxaban	22	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	21	suppressed
Cefdinir	Cefdinir	19	18
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	18	suppressed
Ozempic	Semaglutide	18	suppressed
Synthroid	Levothyroxine Sodium	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	17	suppressed
Atenolol	Atenolol	17	suppressed
Celecoxib	Celecoxib	17	suppressed
Ketoconazole	Ketoconazole	16	12
Nystatin	Nystatin	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	16	12
Alendronate Sodium	Alendronate Sodium	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	15	suppressed
Potassium Chloride	Potassium Chloride	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Victoza 3-Pak	Liraglutide	15	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	12	suppressed
Entresto	Sacubitril/Valsartan	12	suppressed
Jardiance	Empagliflozin	12	suppressed
Methenamine Hippurate	Methenamine Hippurate	12	suppressed
Carbamazepine Er	Carbamazepine	11	suppressed
Cefadroxil	Cefadroxil	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Oxycodone Hcl	Oxycodone Hcl	11	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error